Related Experiment Video
Updated: Aug 8, 2026

Quantitative Structure-Activity Relationship, Activity Prediction, and Molecular Dynamics of Non-nucleotide Reverse Transcriptase Inhibitors
Published on: May 9, 2025
[Entecavir--close perspective for using it]
Waldemar Halota1, Małgorzata Pawłowska
1Katedra i Klinika Chorób Zakaźnych i Hepatologii, Collegium Medicum Uniwersytetu Mikołaja Kopernika w Toruniu. kikchzak@cm.umk.pl
Abstract:
There are 3 drugs registered to treatment of chronic hepatitis B: interferon, lamivudine and adefovir. Many other nucleoside and nucleotide analougs are examined. In experiments on the animals: woodchucks infected with WHBV and ducks infected with DHBV beneficial influence of entecavir on viral DNA and cccDNA supression. In these examination no resistance was present. In clinical studies resistanse to entecavir conserned only patients with resistance to lamivudine. Entecavir is safety and effective in the treatment of chronic hepatits B in patients HBeAg positive and negative and in patients with resistance to lamivudine.
Related Concept Videos
Antiviral Nucleoside Inhibitors
Transmission-based Precautions I: Contact, Enteric, and Droplets
Contact Precautions:
Contact precautions are the measures taken to prevent the transmission of infectious agents, especially epidemiologically important microorganisms such as MRSA or influenza, primarily transmitted through direct or indirect contact with an...
Subviral Agents
Hepatic Drug Excretion: Enterohepatic Cycling
Post-release drugs and metabolites can be reabsorbed into the body from the intestine. For conjugated metabolites like glucuronides, reabsorption requires enzymatic hydrolysis by intestinal microflora. This...
Pharmacokinetics: Drug–Food and Drug–Viral Interactions
Antiprotozoal Agents
